Department Metrics

• Moffitt Cancer Center Support Grant Years 24-27
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.
• Characterization and Targeting of the Epigenetic state underlying uveal melanoma liver metastasis
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Smalley, K.
• State of Florida Appropriation
  Award Number:
  Sponsor: State of Florida
  PI:Cleveland, J.
• Defining and Targeting Epigenetic Plasticity-Driven Drug Resistance and Immune Escape in Melanoma
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Smalley, K.
• Role of ULK3 in Sensitive and Refractory Multiple Myeloma
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Lynch, C.
• Uncovering Causal Protein Markers to Improve Prostate Cancer Etiology Understanding and Risk Prediction in Africans and Europeans
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Wang, L.
• Modulating dendritic cell (DC) polarization and biology with L-fucose to enhance DC vaccine efficacy
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Le-Lau, E.
• Identifying How HDAC Suppression of SLC17A7 Drives Osteosarcoma Progression and Metastasis
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Lynch, C.
• Proprietary arginine vasopressin receptor type 1a (AVPR1a) antagonists for treatment of lethal prostate cancer
  Award Number:
  Sponsor: US Army
  PI:Lynch, C.
• Epigenetic Changes as a Biomarker in African Americans with Papillary Renal Cell Carcinoma and a Link to the Tumor Microenvironment
  Award Number:
  Sponsor: US Army
  PI:Wang, L.
• Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Amelio, A.
• SOW for project management, alliance management, and Executive Sponsors in Major Alliance with Turnstone
  Award Number:
  Sponsor: Turnstone Biologics
  PI:Cleveland, J.
• L-fucose-mediated enrichment of memory CD4+T cells and enhanced anti-melanoma immunity
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Le-Lau, E.
• Extending experimental evolutionary game theory in cancer in vivo to enable clinical translation: integrating spatio-temporal dynamics using mathematical modeling
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Marusyk, A.
• Dissecting Tumor-Immune Interactions in HIV-HPV Co-Infection-Associated Oropharyngeal Cancer using Single Cell Sequencing and Novel Mouse Models
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Amelio, A.
• Optimizing immunotherapy strategies for melanoma brain metastases
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI (Contact):Smalley, K.
• Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Smalley, K.
• Characterization of Plant-Based Phenolic Alkanones as Next-Generation Sun Protectants for Skin Cancer Prevention
  Award Number:
  Sponsor: US Army
  PI (Contact):Premi, S.
• Optimizing the immune mediated-destruction of NRAS mutant melanoma
  Award Number:
  Sponsor: Melanoma Research Alliance (MRA)
  PI (Contact):Smalley, K.,PI:Jaeger, A.
• To assess the efficacy of “Kenvue chemical compounds” in inhibiting incident and delayed cyclobutane pyrimidine dimers (CPDs)
  Award Number:
  Sponsor: Kenvue
  PI:Premi, S.,CO-PI:Srivastava, J.

CLINICAL TRIAL 19319
InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Condition: Genitourinary
Intervention: Ifosfamide (); Not Applicable (); Radiotherapy (); Taxol (paclitaxel); cisplatin (); paclitaxel ()

CLINICAL TRIAL 20386
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Condition: Thoracic
Intervention: Difluoromethylornithine (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20767
Integration of Immunotherapy into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Gemzar (gemcitabine); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); gemcitabine (); paclitaxel ()

CLINICAL TRIAL 20938
A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Condition: Thoracic
Intervention: Not Applicable (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 21184
Thoracic Program Trial Selection Protocol
Condition: Thoracic
Intervention:

CLINICAL TRIAL 21262
A First in Human dose escalation of Dendritic Cell Vaccine (DCV) administered Intrathecally (IT) primed against HER2/HER3 in Patients with Leptomeningeal Disease (LMD) from Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Condition: Neurologic Oncology
Intervention: Dendritic Cell Vaccine ()

CLINICAL TRIAL 21626
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Condition: Thoracic
Intervention: Alimta (Pemetrexed); MK-1084 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin ()

CLINICAL TRIAL 21630
Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab with or without Chemotherapy in Black Patients with NSCLC
Condition: Thoracic
Intervention: Abraxane (); Alimta (Pemetrexed); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); paclitaxel ()

CLINICAL TRIAL 21951
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (STAR-121)
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Domvanalimab (); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); Zimberelimab (); carboplatin (); cisplatin (); paclitaxel ()

CLINICAL TRIAL 22540
A Phase 1, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-130037, a Kelch-like ECH-associated protein 1 (KEAP1) activator, in participants with advanced solid tumors
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); Taxol (paclitaxel); Taxotere (docetaxel); VVD-130037 (); docetaxel (); paclitaxel ()

CLINICAL TRIAL 23160
A Phase 2 Study of Alisertib in Patients with Extensive Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: Alisertib (MLN8237); G-CSF ()

CLINICAL TRIAL 23182
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); Placebo (); V940 ()

CLINICAL TRIAL 23180
A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-line Induction or Maintenance, in Subjects with Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); DS-7300a (I-DXd); I-DXd (); Paraplatin (carboplatin); carboplatin ()

CLINICAL TRIAL 23142
Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer after Neoadjuvant Therapy
Condition: Breast
Intervention: DC1 Vaccine ()

CLINICAL TRIAL 23340
A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer
Condition: Breast
Intervention: Alisertib (MLN8237); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Letrozole (); Tamoxifen (); fulvestrant ()

CLINICAL TRIAL 23572
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Condition: Breast
Intervention: Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Elacestrant (); Exemestane (); Femara (Letrozole); Letrozole (); Tamoxifen ()

CLINICAL TRIAL 23579
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Durvalumab (); MEDI4736 (Durvalumab); Olomorasib/Placebo (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23939
Distinguishing Breast and Cutaneous Tumors
Condition: Breast
Intervention:

• Thatikonda S, Chaudhary R, Meshkovska Y, Biernacki M, Slebos RJC, Song X, Hall MS, Lilley K, Pilon-Thomas S, Guevara-Patino JA, Spiess PE, Chahoud J, Amelio AL, Wachter EA, Rodrigues D, Chung CH. PV-10 Triggers Immunogenic Cell Death in Head and Neck Squamous Cell Carcinoma via Endoplasmic Reticulum Stress and Apoptosis. Mol Cancer Ther. 2025 Nov.24(11):1733-1748. Pubmedid: 40552938. Pmcid: PMC12327362.
• Tian Y, McDonnell SK, Wu L, Larson NB, Wang L. Fine mapping regulatory variants by characterizing native CpG methylation with nanopore long-read sequencing. HGG Adv. 2025 Oct.7(1):100532. Pubmedid: 41109954.
• Solanki HS, Shah H, Imbody D, Desai B, Kato R, Miroshnychenko D, Stern YE, Majumder A, Sarcar B, Xieraili A, Stewart PA, Fang B, Zhang Y, Yao J, Darville LN, Koomen JM, Rix U, Evans JW, Yang YC, Ahler E, Marusyk A, Singh M, Aronchik I, Haura EB. RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer. Cancer Res. 2025 Oct. Pubmedid: 41165456.
• Hesterberg RS, Davis JT, Handoo KJ, Elmarsafawi AG, Augello AC, Cheng CH, Atkins R, Lee DH, Yang C, Yao J, Patel KR, Mediavilla-Varela M, Pinilla-Ibarz J, Soto-Palma C, Locke FL, Song X, Wang X, Berglund AE, Rodriguez PC, Knittel G, Flümann R, Reinhardt HC, Shaw TI, Yu X, Niedernhofer LJ, Cleveland JL. Lymphoma accelerates T cell and tissue aging. Cancer Cell. 2025 Oct.43(10):1917-1936.e8. Pubmedid: 40845845.
• Dong D, Wang Z, Liu M, Zhang Q, Xu W, Wei Y, Zhu J, Yang X, Zhang Q, Zhu Y, Wang L, Zhang P, Wei GH. Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus. Nat Commun. 2025 Oct.16(1):8950. Pubmedid: 41062477. Pmcid: PMC12508145.
• Yadav VK, Srivastava J, Venkatachalam A, Tantak MP, Lawrence NJ, Fisher DE, Lawrence HR, Premi S. Melanin-Driven Delayed CPD Formation Is Independent of Melanin Biosynthesis Pathway. J Invest Dermatol. 2025 Sep. Pubmedid: 40992685. Pmcid: PMC12507450.
• West J, Desai B, Strobl M, Gallaher J, Robertson-Tessi M, Marusyk A, Anderson ARA. Evolutionary antifragile therapy. bioRxiv. 2025 Sep. Pubmedid: 41000654. Pmcid: PMC12458151.
• Park R, Rind F, Kristoff T, Li J, Schell M, Slebos RJC, Thatikonda S, Chaudhary R, Biernacki MI, Meshkovska Y, Kaldas D, Kim HS, Farinhas J, Hernandez-Prera J, Kirtane K, Hall MS, Amelio AL, Rocco JW, Bhateja P, Steuer C, Bonomi M, Saba NF, Chung CH. Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial. Am J Clin Oncol. 2025 Sep. Pubmedid: 40905435.
• Thomas F, Capp JP, Dujon AM, Marusyk A, Asselin K, Campone M, Pujol P, Alix-Panabières C, Roche B, Ujvari B, Gatenby R, Nedelcu AM. Leveraging selection for function in tumor evolution: System-level cancer therapies. Evol Med Public Health. 2025 Aug.13(1):248-268. Pubmedid: 40979445. Pmcid: PMC12448390.
• Sinawang PD, Multani P, Ozen MO, Wong J, Akin D, Hanson C, Larsen M, Ampaw E, Rondina MT, Tolley ND, Wang L, Cunningham BT, Kohli M, Demirci U. Plasma Preparation Strategies for Extracellular Vesicle-Based Biomarkers in Metastatic Castration-Resistant Prostate Cancer. J Extracell Biol. 2025 Aug.4(8):e70071. Pubmedid: 40755906. Pmcid: PMC12311838.
• Milne A, Marusyk A, Maini PK, Anderson ARA, Picco N. The role of environmentally mediated drug resistance in facilitating the spatial distribution of residual disease. Commun Biol. 2025 Aug.8(1):1189. Pubmedid: 40783466. Pmcid: PMC12335614.
• Phadke MS, Li J, Sriramareddy S, Rodriguez PC, Ruffell B, Luca VC, Tran TTT, Chen YA, Smalley KSM. Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models. J Immunother Cancer. 2025 Aug.13(8). Pubmedid: 40825611. Pmcid: PMC12366563.
• Tauro M, Li T, Sudalagunta PR, Meads M, Canevarolo RR, Nerlakanti N, Alugubelli RR, Lawrence HR, Gunawan S, Ayaz M, Nareddy P, Yun SY, Shay G, Yang K, Tran TH, Bishop RT, Nasr MM, Lawrence NNJ, Schönbrunn E, Cleveland JL, Silva AS, Shain KH, Lynch CC. Unc-51 Like Kinase 3 (ULK3) is essential for autophagy and cell survival in multiple myeloma. Res Sq. 2025 Aug. Pubmedid: 40831505. Pmcid: PMC12363935.
• Piña Y, Law V, Sahebjam S, Tran N, Siddarajappa N, Li J, Mo Q, Phadke MS, Arrington J, Macaulay R, Mokhtari S, Evernden B, Ahmed KA, Smalley I, Yu M, Smalley KSM, Forsyth PA. Phase IB Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD) from Solid Tumors: Results and Molecular Analyses. Neurooncol. 2025 Aug. Pubmedid: 40888040.
• Liu S, Zhu J, Zhang H, Zhong H, Wong HTH, Wang L, Wu L. Causal Relationship Between Blood Metabolites and Prostate Cancer Risk: A Two-Sample Mendelian Randomization Study. Mol Carcinogen. 2025 Aug.64(8):1316-1329. Pubmedid: 40387704.
• Musicant AM, Billington JMR, Damrauer JS, Modliszewski JL, Landuau LJB, Tsai YH, Mehta JH, Powers J, Betancourt R, Sekhri R, Padilla RJ, Hernandez-Prera JC, Hayes DN, Hackman TG, Gokcumen O, Knox SM, Amelio AL. An FGFR-p53 developmental signaling axis drives salivary cancer progression. Oncogene. 2025 Aug.44(32):2876-2892. Pubmedid: 40456865.
• Musicant AM, Billington JMR, Damrauer JS, Modliszewski JL, Landau LJB, Tsai YH, Mehta JH, Powers J, Betancourt R, Sekhri R, Padilla RJ, Hernandez-Prera JC, Hayes DN, Hackman TG, Gokcumen O, Knox SM, Amelio AL. Correction: An FGFR-p53 developmental signaling axis drives salivary cancer progression. Oncogene. 2025 Aug.44(32):2924. Pubmedid: 40542202.
• Tyczynska Weh M, Kumar P, Marusyk V, Marusyk A, Basanta D. The adaptive state determines the impact of mutations on evolving populations. Proc Natl Acad Sci U S A. 2025 Jul.122(26). Pubmedid: 40569384. Pmcid: PMC12232665.
• Echevarria M, Park R, Caudell JJ, Kim Y, Yang GQ, Kirtane K, Chaudhary R, Kumar S, Amelio AL, Giuliano AR, Chung CH. Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy. Cancer Res Commun. 2025 Jul.5(7):1194-1202. Pubmedid: 40643202. Pmcid: PMC12281097.
• Yu X, Jain MD, Menges MA, Cen L, Noble JD, Atkins R, Mohammad TJ, Bachmeier CA, Naderinezhad S, Reid K, Corallo S, Yoder SJ, Zhang C, Zhang L, Miranda JA, Shah B, Chavez JC, Hesterberg RS, Delgado LC, Savid-Frontera C, Rodriguez PC, Cleveland JL, Wang X, Davila ML, Locke FL. Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing. J Immunother Cancer. 2025 Jul.13(7). Pubmedid: 40730421. Pmcid: PMC12306477.
• Srivastava J, Yadav VK, Jimenez RV, Phadatare PR, Inamdar NA, Young MM, Bacchiocchi A, Halaban R, Fang B, Pulido AM, Tsai KY, Smalley KSM, Koomen JM, Rodriguez PC, Premi S. Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors. Cancer Res. 2025 Jun.85(12):2268-2287. Pubmedid: 40287947. Pmcid: PMC12167936.
• Bishop RT, Li T, Sudalagunta P, Nasr M, Nyman KJ, Alugubelli RR, Meads M, Frieling J, Nerlakanti N, Tauro M, Fang B, Grant S, Koomen J, Silva AS, Shain KH, Lynch CC. Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myeloma. Haematologica. 2025 Jun.110(6):1351-1367. Pubmedid: 39633543. Pmcid: PMC12130774.
• Xu X, Liu X, Dollar JJ, Liu X, Jasani N, Posorske B, Sriramareddy SN, Jarajapu V, Kuznetsoff JN, Sinard J, Bennett RL, Licht JD, Smalley KSM, Harbour JW, Yu X, Karreth FA. A multi-step immune-competent genetic mouse model reveals phenotypic plasticity in uveal melanoma. bioRxiv. 2025 Jun. Pubmedid: 40502063. Pmcid: PMC12157397.
• Srivastava J, Premi S. Targeting S-Nitrosylation to Overcome Therapeutic Resistance in NRAS-Driven Melanoma. Cancers (Basel). 2025 Jun.17(12). Pubmedid: 40563669. Pmcid: PMC12191001.
• Sun Y, Zhu J, Zhong H, Zhang Z, Wang F, Nakamura A, Liu Y, Liu J, Yu J, Zeng G, Lin X, Zhou D, Wu C, Wang L, Deng Y, Wu L. Transcriptome-Wide Association Study Identified Novel Blood Tissue Gene Biomarkers for Prostate Cancer Risk. Prostate. 2025 May.85(6):567-579. Pubmedid: 39878408.
• Marusyk A. Evolutionary gambit to defeat drug resistance in cancer. Nat Biotechnol. 2025 May.43(5):689-690. Pubmedid: 38965429.
• Kleberg J, Nataraj A, Xiao Y, Podder BR, Jin Z, Tithi TI, Zheng G, Smalley KSM, Moser EK, Safe S, Maharjan CK, Kolb R, Zhang W. Targeting Lineage-Specific Functions of NR4A1 for Cancer Immunotherapy. Int J Mol Sci. 2025 May.26(11). Pubmedid: 40508074. Pmcid: PMC12155124.
• Wong J, Tian Y, Patel MS, Avasthi K, Hanson C, Larsen M, Ampaw E, Fadlullah MZH, Finklestein J, Tan AC, Park J, Manley BJ, Huang CC, Kohli M, Wang L. Plasma Cell-Free DNA Methylation-Based Prognosis in Metastatic Castrate-Resistant Prostate Cancer. Res Sq. 2025 Apr. Pubmedid: 40313768. Pmcid: PMC12045346.
• Desai B, Miti T, Prabhakaran S, Miroshnychenko D, Henry M, Marusyk V, Kumar P, Ozakinci H, Gatenbee C, Bui M, Boyle TA, Scott J, Altrock PM, Haura E, Anderson ARA, Basanta D, Marusyk A. Multifactorial stroma-mediated resistance is a major contributor to residual disease under targeted therapies in lung cancers. Res Sq. 2025 Apr. Pubmedid: 40313737. Pmcid: PMC12045365.
• Renatino Canevarolo R, Sudalagunta PR, Meads MB, Silva M, Zhao X, Magaletti D, Alugubelli RR, DeAvila G, Persi E, Maura F, Bell ET, Bishop RT, Cubitt CL, Sansil SS, Zhang W, Teer JK, Teng M, Yoder SJ, Siegel EM, Shah BD, Nishihori T, Hazlehurst LA, Lynch CC, Landgren O, Hampton O, Gatenby RA, Sullivan DM, Brayer JB, Dalton WS, Cleveland JL, Alsina M, Baz R, Shain KH, Silva AS. Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma. Res Sq. 2025 Apr. Pubmedid: 40321765. Pmcid: PMC12048002.
• Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, O'Neil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli M. Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clin Proteomics. 2025 Apr.22(1):13. Pubmedid: 40251526. Pmcid: PMC12008844.
• Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalainen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L. 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies. Commun Med (Lond). 2025 Mar.5(1):61. Pubmedid: 40038525. Pmcid: PMC11880319.
• Fadlullah MZH, Nix D, Herberts C, Maurice-Dror C, Wyatt AW, Schmidt B, Fairbourn B, Tan AC, Wang L, Kohli M. Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer. JNCI Cancer Spectr. 2025 Mar.9(2). Pubmedid: 40036789. Pmcid: PMC11954629.
• Kato R, Solanki HS, Ozakinci H, Desai B, Gundlapalli H, Yang YC, Aronchik I, Singh M, Johnson J, Marusyk A, Boyle TA, Haura EB. In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRASG12C-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Mar.31(6):1150-1162. Pubmedid: 39836411. Pmcid: PMC11924342.
• Maranto C, Udhane V, Jia J, Verma R, Müller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT. Correction: Maranto et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers 2020, 12, 3412. Cancers (Basel). 2025 Mar.17(6). Pubmedid: 40149386. Pmcid: PMC11940198.
• Hu E, An J, Gersten AJ, Wu N, Kawachi N, Zhu J, Rosenblatt G, Augustine S, Smith RV, Segall JE, Ostrer H, Amelio AL, Chung CH, Prystowsky MB, Ow TJ, Deng W, Yin S. Virusplot: a web server for viral integration analysis and visualization. Front Oncol. 2025 Feb.15:1539782. Pubmedid: 40046621. Pmcid: PMC11880266.
• Avasthi KK, Choi JW, Glushko T, Manley BJ, Yu A, Park JY, Brown JS, Pow-Sang J, Gatenby R, Wang L, Balagurunathan Y. Extracellular Microvesicle MicroRNAs and Imaging Metrics Improve the Detection of Aggressive Prostate Cancer: A Pilot Study. Cancers (Basel). 2025 Feb.17(5). Pubmedid: 40075682. Pmcid: PMC11898942.
• Kim SG, Tasoulas J, Sheth S, Yarbrough WG, Hackman T, Amelio AL, Sullivan CB. The Role of Immunotherapy in Salivary Gland Cancer: A Systematic Review. Ear Nose Throat J. 2025 Feb. Pubmedid: 40018983.
• Wong J, Muralidhar R, Wang L, Huang CC. Epigenetic modifications of cfDNA in liquid biopsy for the cancer care continuum. Biomed J. 2025 Feb.48(1):100718. Pubmedid: 38522508. Pmcid: PMC11745953.
• Sudalagunta PR, Canevarolo RR, Meads MB, Silva M, Zhao X, Cubitt CL, Sansil SS, DeAvila G, Alugubelli RR, Bishop RT, Tungesvik A, Zhang Q, Hampton O, Teer JK, Welsh EA, Yoder SJ, Shah BD, Hazlehurst L, Gatenby RA, Van Domelen DR, Chai Y, Wang F, DeCastro A, Bloomer AM, Siegel EM, Lynch CC, Sullivan DM, Alsina M, Nishihori T, Brayer J, Cleveland JL, Dalton W, Walker CJ, Landesman Y, Baz R, Silva AS, Shain KH. The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma. Cancer Res. 2025 Jan.85(2):378-398. Pubmedid: 39476082. Pmcid: PMC11733535.
• Tomczak K, Patel MS, Bhalla AD, Peterson CB, Landers SM, Callahan SC, Zhang D, Wong J, Landry JP, Lazar AJ, Livingston JA, Guadagnolo BA, Lyu HG, Lillemoe H, Roland CL, Keung EZ, Scally CP, Hunt KK, McCutcheon IE, Slopis JM, Gu J, Scheet P, Wang L, Rai K, Torres KE. Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1. Mol Carcinogen. 2025 Jan.64(1):44-56. Pubmedid: 39600120. Pmcid: PMC11636586.
• Seedor RS, Aplin AE, Bertolotto C, Carvajal RD, Deacon N, Doble K, Hamid O, Haq R, Kadosh M, Khan S, Kraska J, Lutzky J, McKean M, Montazeri K, Moser J, Onken M, Orloff M, Sacco JJ, Smalley K, Selig SM. Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023. Pigment Cell Melanoma Res. 2025 Jan.38(1):e13205. Pubmedid: 39385554.
• Liu S, Zhu J, Green D, Zhong H, Long Q, Wu C, Wang L, Deng Y, Wu L. Integrating Multi-Omics Data to Uncover Prostate Tissue DNA Methylation Biomarkers and Target Genes for Prostate Cancer Risk. Mol Carcinogen. 2025 Jan.64(1):83-90. Pubmedid: 39400371.
• Tejero JD, Hesterberg RS, Drapela S, Ilter D, Raizada D, Lazure F, Kashfi H, Liu M, Silvane L, Avram D, Fernández-García J, Asara JM, Fendt SM, Cleveland JL, Gomes AP. Methylmalonic acid induces metabolic abnormalities and exhaustion in CD8+ T cells to suppress anti-tumor immunity. Oncogene. 2025 Jan.44(2):105-114. Pubmedid: 39472497.
• Frieling JS, Lynch CC. Tales of Cancer-Induced Bone Disease from the Senescent Osteocyte Crypt. Cancer Res. 2024 Dec.84(23):3917-3918. Pubmedid: 39618247.
• Nerlakanti N, McGuire J, Bishop RT, Nasr M, Li T, Reed D, Lynch CC. Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for pulmonary metastasis. Cancer Lett. 2024 Dec.606:217302. Pubmedid: 39427726.
• Li T, Patel KB, Yu X, Yao S, Wang L, Chung CH, Wang X. Identifying targeted cell-free DNA methylation regions in head and neck cancer via paired methylome analysis. Res Sq. 2024 Nov. Pubmedid: 39649173. Pmcid: PMC11623779.